

Breakfast Briefing presentation title:
PET as a decision making tool in early clinical development of CNS
molecules

Interactive presentation reviewing strategic, scientific and operational aspects for developing and integrating Positron Emission Tomography (PET) during first-in-man studies, as a biomarker to assess receptor occupancy, in order to achieve “go/no-go” decisions and dose regimen recommendations for further studies.

Some practical examples of early clinical development plans including PET strategy associated with additional pharmacodynamic biomarkers were illustrated with selected central nervous system (CNS) molecules.

Submitted for oral presentation at the Exploratory Clinical Development World Europe, London May 2009

Speakers: Mr. Denis GOSSEN, Director and Clinical Research Scientist Advisor